A Resolution designating the month of May 2025 as "Amyotrophic Lateral Sclerosis Awareness Month" in Pennsylvania.
Take action
Record your position on this measure.
Create an account to take a stance, submit a written position, or contact your legislator.
Progress
Where this bill stands in the legislative process.
- Introduced
- Passed House
- Passed Senate
- To Governor
- Became Law
Overview
This resolution designates May 2025 as "Amyotrophic Lateral Sclerosis Awareness Month" in Pennsylvania. The resolution aims to raise public awareness about ALS, a fatal neurodegenerative disease, and acknowledge its impact on patients and families. It recognizes ongoing research efforts to find a cure for this disease.
Key provisions
- Designates May 2025 as "Amyotrophic Lateral Sclerosis Awareness Month" in Pennsylvania.
- Highlights the characteristics of ALS, including muscle weakness, difficulty swallowing and speaking, and eventual paralysis.
- States that ALS has no known cause, prevention, or cure.
- Mentions the approximate number of new ALS diagnoses annually (around 5,000).
- Notes the average survival time for ALS patients (2-5 years).
- Acknowledges the higher prevalence of ALS in men.
- Recognizes the impact of the disease on patients and their families.
- Supports research efforts to eradicate ALS.
Who is affected
- Individuals with Amyotrophic Lateral Sclerosis (ALS)
- Families and caregivers of individuals with ALS
- Pennsylvania residents
- Healthcare professionals
- Researchers studying ALS
Notable changes
- This resolution does not represent a change to existing laws or policies.
Bill text
Read the latest version inline or switch to a previous version.
Document of record
- Version
- Pn 1215 Html
- Published
- Not published in the source record
This version is published only as a document. Open the viewer to read it here, or download the file.
Sponsors
Official sponsors from legislative records.
9 on record
Primary sponsor
Cosponsors
Jose Giral
Arguments
Reasons offered for and against this legislation.
Arguments in favor
No arguments in favor have been submitted.
Submit yoursArguments opposed
No arguments opposed have been submitted.
Submit yours